Following up its March deal with Bristol-Myers Squibb Co. (BMS) centered on a pair of undisclosed checkpoint inhibitors, Five Prime Therapeutics Inc. entered a new arrangement with BMS that brings $30 million up front and may hold the key to getting around resistance problems.